Seattle Seahawks Withdraw from Joe Mixon: How a Physical Rewrote a Deal

Joe Mixon was very close to Seattle. According to ESPN's Adam Schefter, the Pacific Northwest club and Mixon had reached an agreement to place him on the practice squad. One day later, the deal collapsed. No dispute over money, no last-minute call from a rival club, no announced change of heart. Only a physical exam, and a signature that was never put to paper.

In thirty years of watching the transfer market, I have learned that the most powerful gates are often the quietest. The medical gate is one of them. It never appears on the news ticker, holds no press conference, issues no formal statement of explanation. Yet it can end a career within hours, faster than any injury suffered on the field.

"France Bleu taught me one thing: unverified, never on air." In 2026, at the age of twenty-three, I once read out on air that Ronaldinho was about to join Manchester United, based only on an unverified article. Seventeen complaint calls, a full-page apology letter, and a lesson that has stayed with me for life: the truth is not in the headline, but in what insiders choose not to say.

In Seattle, what went unsaid was the result of the physical exam. And that is where the real story begins.

To understand why a team short of bodies would reject a former Pro Bowl player, this deal needs to be placed in its proper context, because reading only the headline makes it easy to misjudge both sides.

Joe Mixon, aged thirty, is one of the most prolific running backs of the past decade. Five consecutive seasons above one thousand rushing yards. In his last full season, he recorded 1,016 rushing yards and eleven touchdowns, enough to earn a Pro Bowl berth. It is a résumé any NFL coaching room would look up to, and the reason he was once a cornerstone of the Cincinnati Bengals before moving to the Houston Texans.

But that résumé is now old. Mixon has not played a single game since January 2026. The entire previous season, he was absent with a foot injury. He was released by the Houston Texans, and in the words of general manager Nick Caserio, it was an "unusual situation" - a loaded phrase that investigators like me always pay attention to.

On Seattle's side, the story lies in the locker room. Jadarian Price, a rookie, was placed on injured reserve with a chest issue. Zach Charbonnet is recovering from anterior cruciate ligament surgery. The backfield was so empty that two little-known names, Emanuel Wilson and George Holani, suddenly became reluctant pillars.

That is why Seattle turned to Mixon. Not because he fits a specific scheme, but because they needed an experienced body to fill the immediate gap. And that is precisely why this deal was fragile from its very first moment.

Reading a deal does not require listening to rumors, only watching where the money flows. But in the NFL, there is another kind of flow more important than money: the flow of health. And in the Mixon deal, that flow was blocked at the door.

The decisive variable in this deal was not tactics, but medicine. In the European-style football I know, people argue about formations, about roles, about how a player fits a coach's system. In the NFL, the first question is always: can this body still hold up? Seattle changed its stance after the physical exam. A short sentence, but it says everything. The club did not see a thirty-year-old running back with five thousand-yard seasons. They saw a foot that had not healed.

What stands out is that Seattle never regarded Mixon as an indispensable piece. The leaked agreement was for a practice-squad spot, not an active-roster spot. This is a detail many readers skip over, but it changes the entire understanding of the deal. The practice squad is where low-risk experiments live, where a player can be cut at any moment without costing a single cent against the salary cap. A former Pro Bowl player being offered a practice-squad spot, rather than an active-roster spot, is the most precise measure of how far the running back position has depreciated in modern American football.

One word on the credibility of the sources. ESPN's Adam Schefter is one of the most trusted sports journalists in America, and Nick Caserio is the sitting general manager of the Houston Texans. When both names appear in the same story, we can trust the core of the event: the deal collapsed, and the reason was medical. What we do not know, and perhaps will never fully know, is exactly what was found in the examination.

Look at the age figure. Running back is the position with the steepest decline curve in the entire sport. Its peak usually falls between the ages of twenty-four and twenty-seven, and after twenty-eight, value collapses faster than at any other position on the field. Mixon is thirty, missed an entire season, with a foot injury not confirmed as healed. Three depreciation signals combine into a conclusion any financial analyst would recognize: this asset is losing value, not gaining it.

I used to bring a spreadsheet into the studio to explain deals like this to French listeners. But there is a limit every number must bow to: you cannot calculate a foot. No dataset can tell you whether an injury will recur. That is why the physical exam, even though it is never broadcast, is the most important document in an entire deal file.

And here is where I want to pause, because it concerns how the NFL operates. Unlike European football, where a club can offload a bad contract to another team or bury it as a loan, the NFL operates under a hard salary cap. Every active-roster spot is a real occupation of financial space, and there is no way to write it off with an accounting entry. When Seattle decided not to sign Mixon after he failed the physical, they were not just protecting a foot. They were protecting a roster spot, and that spot is a scarce asset.

A contract is the record of greed, but also the diary of hope. In this case, the contract was never signed. But that diary still tells a story: the story of a player who believes he can still play, and a club that believes it can find someone better with less risk.

There is one thing I always remind my listeners: do not confuse necessity with recklessness. Seattle needed a running back. But they did not need one so badly that they had to gamble on an unverified body. The difference between these two things is the difference between a mature club and a desperate one.

An insider is not the person who knows the most, but the person who stays calmest when everything collapses. Seattle stayed calm. They took the information from the exam, weighed it, and withdrew. Meanwhile, the rest of the market is reading that signal in a very different way: if a team this short of bodies still says no, then Mixon's problem is more serious than appearances suggest.

But there is another side to the story, and it lies in what Seattle achieved without Mixon. In the 30-23 win over the Los Angeles Chargers, their offense still functioned. Emanuel Wilson rushed for 81 yards and a touchdown on 21 carries, plus 39 receiving yards and another score. It was a performance any running back could be proud of. And it had a direct effect on the deal: once a club discovers it can still win without the man in question, the pressure to sign him drops significantly.

This is logic that transfer reporters sometimes overlook. We tend to think of deals in terms of a club's need, but that need is not fixed. It stretches with each game, with each performance by the replacements. Seattle did not reject Mixon only because of his foot. They rejected him because a knee had healed elsewhere, and because a young man named Emanuel Wilson grabbed the opportunity with both hands.

But here is where I want to pose a counterintuitive question, because the story told in the press has been oversimplified, and sometimes dramatized to the point of obscuring the truth.

The media's telling of this event is easy to predict: an aging player, a missed season, a failed physical, and a career about to end. It is a sad story, tidy, and convenient for the reader. But it misses an important blind spot: we are viewing a medical gate as though it were a final verdict, when in reality it is only the standard of one specific club, at one specific moment.

Medical thresholds in the NFL are not a universal constant across the league. Each club has its own medical staff, with different risk tolerances. A team in a championship race may reject an unhealed foot because it cannot gamble on a precious roster spot. But a rebuilding team, under less pressure for results, could well accept that risk in exchange for experience and a weighty name in the locker room. In other words, Seattle's rejection does not mean Mixon has no door left in the NFL. It only means he has no door in Seattle, at this moment.

There is another detail I want to emphasize, and it belongs to the cultural difference between the two football worlds. In European football, when a deal collapses over a medical, people tend to blame the club's excessive caution, its bureaucracy, its lack of faith in the player. In the NFL, the reaction is different. The physical is treated as a legitimate risk-management tool, an inevitable part of the game. This difference is worth noting: the same event, two football cultures, two ways of reading it. And it reminds me that, as a Vietnamese man working in France, I must always be careful not to impose my European lens on a league that operates on entirely different logic.

And there is a deeper layer I do not want to skip over. Mixon's story reflects a trend far larger than one individual's fate. Running backs are being repriced across the league. The men who were once the center of the offense are now regarded as short-lived, fragile, easily replaced assets. A player with five thousand-yard seasons being offered a practice-squad spot is a signal, not an exception. When a position is repriced, those at the end of the career curve are always the first to pay.

I have seen the same thing in esports, where a competitor's career is far shorter than a footballer's, yet the youth-development and post-retirement support system is nearly nonexistent. What the two worlds share is this: when a system is not designed to protect workers at the end of their careers, the final gate - whether the medical gate or the age gate - will always close coldly.

So when someone asks me whether this is the end for Joe Mixon, I answer that the right question is not "can Mixon still play", but "is there still a team willing to take that risk". And the answer to the second question depends on a variable none of us controls: the result of the next physical exam.

At forty-six, I no longer chase breaking news; I chase verified truth. And the truth here is this: the Mixon deal did not fail for lack of talent, but because of a medical standard. It is a gate that no news ticker ever broadcasts, yet it holds the power to determine the fate of an entire career.

What I am waiting for next is not a statement from Seattle, but whether another club puts Mixon on the examination table. If one does, and if he passes, we will know that Seattle's medical threshold is stricter than the rest. If no team calls, then that gate has closed on an entire generation of running backs.

Football, whether in Europe or America, is always told through goals. But sometimes the real story lies in a room with no audience, where a doctor turns over a page of results, and an entire career changes with it.